Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings

KRYS·Reported May 6, 2025·Before market open

Krystal Biotech, Inc. reported Q1 2025 revenue of $88.2M (+94.9% YoY), missed analyst consensus of $106.0M by $17.8M. Diluted EPS came in at $1.20 (+3900.0% YoY), missed the $1.38 consensus by $0.18.

Revenue
$88.2Mmissed by $17.8M
Consensus: $106.0M
Diluted EPS
$1.20missed by $0.18
Consensus: $1.38
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001711279-25-000044

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Krystal Biotech, Inc.'s Q1 2025 earnings report.

Krystal Biotech, Inc. (KRYS) reported Q1 2025 earnings on May 6, 2025 before market open.

Krystal Biotech, Inc. reported revenue of $88.2M and diluted EPS of $1.20 for Q1 2025.

Revenue missed the consensus estimate of $106.0M by $17.8M. EPS missed the consensus estimate of $1.38 by $0.18.

Compared to the same quarter a year prior, revenue grew 94.9% from $45.3M a year earlier and diluted EPS grew 3900.0% from $0.03.

You can read the 10-Q periodic report (0001711279-25-000044) directly on SEC EDGAR. The filing index links above go to sec.gov.